How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,908 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

15821. 308-nm excimer laser for the treatment of psoriasis: induration-based dosimetry. Full Text available with Trip Pro

308-nm excimer laser for the treatment of psoriasis: induration-based dosimetry. To determine the response of stubborn psoriatic plaques to the 308-nm excimer laser.Controlled study with a before-after design.A university-based clinical research center.Adult subjects with recalcitrant plaque psoriasis that have not responded to other therapies for at least 2 months.Selected psoriatic plaques were treated with the 308-nm excimer laser. One lesion was left as a control. Each plaque was treated 2 (...) times a week, with an initial dose based solely on the induration component of the modified Psoriasis Area and Severity Index score for that lesion. Subsequent treatments were twice a week with dosage increments up to 50%, based on the change in induration. Four final consolidation doses were given once the induration score was reduced to zero.Eighteen subjects were treated. There were 4 dropouts because of various scheduling problems. In the remaining 14 subjects, 44 plaques received a mean of 10

2003 Archives of Dermatology

15822. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Full Text available with Trip Pro

Efficacy of acitretin and commercial tanning bed therapy for psoriasis. To assess the efficacy of acitretin and commercial tanning bed therapy for the treatment of moderate to severe chronic plaque-type psoriasis.Retrospective medical record review and telephone survey of subjects and prospective open-label trial.University dermatology clinic.The study population comprised 26 subjects in the retrospective study and 17 subjects in the prospective study, all with moderate to severe plaque-type (...) psoriasis.Twelve weeks of daily oral acitretin (25 mg) therapy and commercial tanning bed UV exposure (mean UV-B output of 4.7%) for 4 to 5 days per week.In the retrospective review, 19 (83%) of 23 subjects had clearance or near clearance, 2 (9%) of 23 had moderate improvement, and 2 (9%) of 23 had no improvement. Patients reported a high degree of satisfaction with the treatment. In the prospective trial, the Psoriasis Area and Severity Index (PASI) and National Psoriasis Foundation scores decreased

2003 Archives of Dermatology

15823. Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. (Abstract)

Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. Atopic dermatitis (AD) and psoriasis are the two most common chronic inflammatory skin diseases. Both of these diseases have distinct clinical findings and specific inflammatory cell infiltrates. Previous reports have focused individually on one or two genes or gene products in the lesions of both skin diseases. However, they have not captured the complex gene expression (...) that must occur to induce specific cellular infiltrates in the skin lesions of these two diseases. DNA microarray studies allow the simultaneous comparison of thousands of messenger RNAs that may identify the disease-specific pattern of tissue inflammatory responses.To compare the complex gene expression pattern of AD versus psoriasis skin lesions.RNA was extracted from skin biopsy specimens of 6 patients with AD and 7 patients with psoriasis and analyzed with the use of Hu-U95Av.GeneChip microarrays

2003 Journal of Allergy and Clinical Immunology

15824. Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. (Abstract)

Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. Both atopic dermatitis (AD) and psoriasis vulgaris (PsV) are characterized as chronic and relapsing inflammatory skin diseases associated with various immunologic abnormalities. Cutaneous T cell-attracting chemokine (CTACK; CCL27) is a member of the CC chemokine family and a functional ligand for CC chemokine receptor 10. It is selectively expressed in skin (...) significantly higher than those in healthy control subjects. The serum CTACK levels in patients with AD significantly correlated with scoring atopic dermatitis (SCORAD) scores, serum soluble IL-2 receptor levels, serum soluble E-selectin levels, serum thymus and activation-regulated chemokine levels, and serum macrophage-derived chemokine levels. Serum CTACK levels in patients with PsV significantly correlated with the serum IP-10 levels but not with the Psoriasis Area and Severity Index score

2003 Journal of Allergy and Clinical Immunology

15825. Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis. (Abstract)

Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis. The effects of acitretin (free acid of etretinate) on the serum lipoprotein pattern and on the fat elimination in serum of 8 patients with psoriasis and 4 with palmo-plantar pustulosis were studied. The drug was given for 12 weeks; the average daily dose was 40 mg. Lipoprotein analyses and an intravenous fat tolerance test (IVFTT) were performed on three occasions (before, after 8 weeks

1988 Acta Dermato-Venereologica

15826. Treatment of psoriasis vulgaris by oral administration of 1 alpha-hydroxyvitamin D3--open-design study. (Abstract)

Treatment of psoriasis vulgaris by oral administration of 1 alpha-hydroxyvitamin D3--open-design study. In an open-design study 1 alpha-hydroxyvitamin D3 was administered orally to 17 patients with psoriasis vulgaris at a dose of 1.0 micrograms/day for 6 months. More than moderate improvement was observed in 13 (76%) of the 17 patients from 2.7 +/- 0.6 months (mean +/- SD) after the start of treatment. No side effects of the treatment were observed. The mechanism of the effect of 1 alpha (...) -hydroxyvitamin D3 requires study, but these data suggest that its oral administration is effective for treatment of psoriasis vulgaris.

1986 Calcified tissue international

15827. Short contact anthralin in the treatment of psoriasis: a study of different contact times. (Abstract)

Short contact anthralin in the treatment of psoriasis: a study of different contact times. Eighteen patients with chronic plaque psoriasis were investigated in two groups to determine the optimal contact time for the application of 2% anthralin, within the range immediate removal to removal at 20 min. It was found that clinical efficacy, assessed by times to plaque clearing, and side effects of treatment, i.e. erythema and staining, were independent of anthralin contact time. There seemed

1986 The British journal of dermatology

15828. Psoriasis treatment: faster clearance when UVB-dithranol is combined with topical clobetasol propionate. (Abstract)

Psoriasis treatment: faster clearance when UVB-dithranol is combined with topical clobetasol propionate. Fifty patients with plaque psoriasis were treated with dithranol and UVB 5 days per week. Twenty-six of these patients also received 13 treatments (once daily in the 1st week, every other day in the 2nd week, twice in the 3rd week and once in the 4th week) with topical clobetasol propionate. The median time for clearance was 2.5 weeks for those on the clobetasol propionate-dithranol-UVB (...) 7 of 18 versus 4 of 15) but the differences were not statistically significant. The study shows that addition of topical clobetasol propionate according to our schedule to the traditional dithranol-UVB regimen of psoriasis results in a more rapid clearance of lesions without undesirable side effects.

1986 Dermatologica

15829. Sulfasalazine: a potential psoriasis therapy? (Abstract)

Sulfasalazine: a potential psoriasis therapy? In an open study, 32 patients with moderate to severe stable plaque psoriasis were treated with sulfasalazine, 3 gm daily for 8 weeks. Twenty-four patients completed the study, and 19 had modest to marked improvement or clearing. If confirmed by a double-blind study, sulfasalazine could become an alternative therapy in some patients with moderate to severe psoriasis.

1989 Journal of the American Academy of Dermatology

15830. Addition of a topically applied corticosteroid to a modified Goeckerman regimen for treatment of psoriasis: effect on duration of remission. (Abstract)

Addition of a topically applied corticosteroid to a modified Goeckerman regimen for treatment of psoriasis: effect on duration of remission. A double-blind parallel group study was undertaken to assess the effect of adding a topically applied corticosteroid cream to a modified Goeckerman regimen to treat patients with psoriasis. Nineteen patients with psoriasis were treated with either this regimen and hydrocortisone valerate cream or the regimen and vehicle cream. Patients were given daily

1986 Journal of the American Academy of Dermatology

15831. Rationally designed combination chemotherapy for the treatment of patients with recalcitrant psoriasis. (Abstract)

Rationally designed combination chemotherapy for the treatment of patients with recalcitrant psoriasis. In an effort to improve clinical response and reduce systemic toxicity, nine patients with recalcitrant psoriasis were treated with rational combinations of chemotherapeutic agents. Five patients received methotrexate by injection, 7.5 or 10 mg, followed 1 hour later by intravenous 5-fluorouracil, 170 to 562 mg/m2, on a weekly schedule. Four patients received oral triacetyl-azauridine, 2 to 4 (...) and effective alternative for the therapy of patients with severe psoriasis.

1986 Journal of the American Academy of Dermatology

15832. Additional effect of grenz rays on psoriasis lesions of the scalp treated with topical corticosteroids. (Abstract)

Additional effect of grenz rays on psoriasis lesions of the scalp treated with topical corticosteroids. In a double-blind study comprising 17 patients with symmetrical psoriasis lesions of the scalp, the combination of grenz ray treatment and topical steroid showed a faster clearing than with the topical steroid alone. The results also indicate a longer remission time with the combination therapy compared to grenz rays alone. Therefore both the faster clearing and the longer remission time (...) with the combination therapy, as compared to our previous study of grenz ray treatment of scalp psoriasis, are probably due to the additional effect of steroid therapy, on grenz rays.

1988 Dermatologica

15833. [Ethacizine in the treatment of psoriasis]. (Abstract)

[Ethacizine in the treatment of psoriasis]. Ethacizine (2-carbethoxyamino-10 (3-diethylaminopropionyl) phenothiazine hydrochloride) has been administered in a daily dose of 150-200 mg for 8-10 weeks to 46 patients with diffuse psoriasis. The treatment has been effective in 84.8% of the patients. Late results, followed up over a year in 40 patients, are fine.

1989 Vestnik dermatologii i venerologii

15834. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. (Abstract)

Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. The purpose of this double-blind study was to compare the therapeutic effects of a low initial dosage of acitretin, increased at 2-week intervals (group 1: 10, 30, 50 mg/day) with a high initial dosage decreased at similar intervals (group 3: 50, 30, 10 mg/day) and with a constant dosage (group 2: 30 mg/day) in 66 patients (47 men and 19 women) with severe psoriasis. At the end of the double (...) -blind phase, the mean percent improvement, calculated by the Psoriasis Area and Severity Index score, was as follows: 62.7% in group 1, 55.9% in group 2 and 67.1% in group 3. The double-blind phase of 6 weeks was followed by an open phase of 6 weeks, during which the patients were treated either with 10, 30 or 50 mg/day, according to the therapeutic response. At the end of treatment (12 weeks), a mean improvement of more than 80% was obtained in all three groups. Hypervitaminosis A signs

1989 Dermatologica

15835. Acitretin treatment of severe psoriasis. (Abstract)

Acitretin treatment of severe psoriasis. Fourteen male patients suffering from severe psoriasis were treated with 30 to 50 mg/day acitretin during 12 weeks. At the end of the treatment, 6 patients were in remission and 7 showed a marked improvement of the disease. One patient did not show any change. All patients experienced the usual retinoid side effects.

1990 Acta dermato-venereologica. Supplementum

15836. Comparative study of desoximetasone ointment 0.25% versus fluocinonide ointment 0.05% in patients with psoriasis. (Abstract)

Comparative study of desoximetasone ointment 0.25% versus fluocinonide ointment 0.05% in patients with psoriasis. In a multicenter, investigator-blind study, desoximetasone ointment 0.25% was compared with fluocinonide ointment 0.05% in the treatment of patients with psoriasis. Evaluations were made before treatment and after 4, 7, and 14 days of treatment. Both drugs were shown to be safe and effective. Desoximetasone was significantly superior to fluocinonide in improving severity scores from

1986 Clinical therapeutics

15837. Trimethylpsoralen bath plus ultraviolet A combined with oral retinoid (etretinate) in the treatment of severe psoriasis. (Abstract)

Trimethylpsoralen bath plus ultraviolet A combined with oral retinoid (etretinate) in the treatment of severe psoriasis. Twenty five patients with severe and extensive psoriasis were treated with trimethylpsoralen (trioxsalen) bath plus ultraviolet A (bath PUVA) combined with oral retinoid, etretinate (Ro 10-9359). Etretinate was started (1 mg/kg/day) 2 weeks prior to starting the bath PUVA treatment daily. Psoriasis cleared with fifteen treatments in 96% of patients with a mean total UVA dose (...) of treatment were good or excellent in fourteen of fifteen patients (93%) getting only bath PUVA one to two times a week and in four of nine patients (44%) getting etretinate (25-50 mg daily) in a mean follow-up time of 10 weeks. These results show the benefits of the combination of trimethylpsoralen bath PUVA with an oral retinoid, etretinate, in the treatment of severe and extensive psoriasis.

1985 Journal of the American Academy of Dermatology

15838. Group therapy of psoriasis. Duo formula group treatment (DFGT) as an example. (Abstract)

Group therapy of psoriasis. Duo formula group treatment (DFGT) as an example. Between 1978 and 1982 an experiment on group treatment for and by psoriasis sufferers was conducted, based on a pyramid of previous investigations since 1968. Each group was facilitated by a duo consisting of a fellow sufferer and a physician, both having trained together. The subjects practiced the procedure described, directed toward self-care and mutual aid facilitated and supported by the duo, in a series of ten 2

1985 Journal of the American Academy of Dermatology

15839. Dermatology—Epitomes of Progress: Newer Aspects of the Use of Anthralin in Psoriasis Full Text available with Trip Pro

Dermatology—Epitomes of Progress: Newer Aspects of the Use of Anthralin in Psoriasis 18748765 2010 06 30 2018 11 13 0093-0415 134 1 1981 Jan The Western journal of medicine West. J. Med. Dermatology-epitomes of progress: newer aspects of the use of anthralin in psoriasis. 44-5 Goldberg L H LH Stewart M M eng Journal Article United States West J Med 0410504 0093-0415 1981 1 1 0 0 1981 1 1 0 1 1981 1 1 0 0 ppublish 18748765 PMC1272450 J Cutan Pathol. 1977 Oct;4(5):233-43 342554 Br J Dermatol

1981 Western Journal of Medicine

15840. Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Full Text available with Trip Pro

Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Patients with ankylosing spondylitis, psoriatic arthritis, and psoriasis alone were typed for HLA A, B, Cw, and DR antigens, and the antigen frequencies were compared with those in a normal control population and in patients with rheumatoid arthritis. Patients with psoriasis had a significantly raised frequency of Cw6. Those with arthritis in addition to their psoriasis also had raised frequencies

1983 Annals of the Rheumatic Diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>